SNBIF Quote, Financials, Valuation and Earnings

Healios KK has a net margin of -- compared to SanBio's net margin of -6742.11%. SanBio's return on equity of -- beat Healios KK's return on equity of -196.15%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio has higher upside potential than Healios KK, analysts believe SanBio is more attractive than Healios KK.

SanBio has a beta of -0.584, which suggesting that the stock is 158.36% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than Healios KK quarterly revenues of $249.2K. SanBio's net income of -$10.3M is higher than Healios KK's net income of -$16.8M. Notably, SanBio's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 111.14x versus 76.64x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of -- compared to SanBio's net margin of -24.41%. SanBio's return on equity of -- beat PeptiDream's return on equity of 34.1%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio has higher upside potential than PeptiDream, analysts believe SanBio is more attractive than PeptiDream.

SanBio has a beta of -0.584, which suggesting that the stock is 158.36% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than PeptiDream quarterly revenues of $27.8M. SanBio's net income of -$10.3M is lower than PeptiDream's net income of -$6.8M. Notably, SanBio's price-to-earnings ratio is -- while PeptiDream's PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 111.14x versus 4.76x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of -- compared to SanBio's net margin of -11.44%. SanBio's return on equity of -- beat Nxera Pharma's return on equity of -8.65%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio has higher upside potential than Nxera Pharma, analysts believe SanBio is more attractive than Nxera Pharma.

SanBio has a beta of -0.584, which suggesting that the stock is 158.36% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio pays -- of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than Nxera Pharma quarterly revenues of $43.6M. SanBio's net income of -$10.3M is lower than Nxera Pharma's net income of -$5M. Notably, SanBio's price-to-earnings ratio is -- while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 111.14x versus 2.91x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of -- compared to SanBio's net margin of -9.79%. SanBio's return on equity of -- beat Takeda Pharmaceutical's return on equity of 1.49%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.15 which suggests that it could grow by 14.63%. Given that Takeda Pharmaceutical has higher upside potential than SanBio, analysts believe Takeda Pharmaceutical is more attractive than SanBio.

SanBio has a beta of -0.584, which suggesting that the stock is 158.36% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.347%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.1% to investors and pays a quarterly dividend of $0.33 per share. SanBio pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. SanBio's net income of -$10.3M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, SanBio's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 69.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 111.14x versus 1.61x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.